Sanofi $SNY Stock Position Increased by Brooklyn Investment Group

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Brooklyn Investment Group grew its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 496.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,748 shares of the company's stock after buying an additional 8,113 shares during the period. Brooklyn Investment Group's holdings in Sanofi were worth $541,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of SNY. Accent Capital Management LLC bought a new position in Sanofi during the 1st quarter worth approximately $29,000. Eastern Bank lifted its holdings in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares during the last quarter. Brentview Investment Management LLC bought a new stake in shares of Sanofi in the 1st quarter worth approximately $42,000. Finally, UMB Bank n.a. lifted its holdings in shares of Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after purchasing an additional 264 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

SNY traded up $0.08 during trading hours on Thursday, hitting $50.61. The company's stock had a trading volume of 1,491,271 shares, compared to its average volume of 2,786,033. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $124.27 billion, a PE ratio of 12.17, a PEG ratio of 1.21 and a beta of 0.48. The company has a 50-day simple moving average of $48.59 and a 200 day simple moving average of $51.74.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the prior year, the firm posted $1.73 EPS. The firm's quarterly revenue was down 7.0% on a year-over-year basis. As a group, sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several recent research reports. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Finally, Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Three analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.